H1 and Q2 2026 results


For investor audiences and financial/business media only


Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030


In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets.

We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.

Pascal Soriot Chief Executive Officer, AstraZeneca

Downloads

Announcement

Presentation

Clinical trials appendix


Key performance elements for H1 2026

(Growth numbers at constant exchange rates)

  • Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease

  • Core Operating profit and Core EPS increased 11%

  • Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)

  • 30 approvals in major regions since Q4 2025 results


Total Revenue
$30.7bn
% Change at CER1
▲ 6%
Core2 EPS
$5.21
▲ 11% CER
Core Operating Profit
$10.5bn
▲ 11% CER


How did AstraZeneca perform financially?

Revenue and EPS Summary H1 2026 Q2 2026
$m % Change Actual % Change CER $m % Change Actual % Change CER
Product Sales 28,896  8 5 14,510  5 4
Alliance Revenue 1,699  31 29 874 34 33
Product Revenue 30,595  9 6 15,384  6 5
Collaboration Revenue 77 (6) (9) - n/m n/m
Total Revenue 30,672  9 6 15,384  6 5
Reported EPS ($) 3.60 4 3 1.61 2 (2)
Core EPS ($) 5.21 12 11 2.63 21 18

FY2026
GUIDANCE3
RECONFIRMED
At CER, Total Revenue is expected to increase by a mid-to-high single-digit % and Core EPS by a low double-digit %. The Core Tax rate is expected to be between 18–22%.


Which Therapy Areas drove growth?

H1 2026 Total Revenue by Therapy Area. Growth at CER.

Oncology
▲ 15%
$14.1bn

46% of revenue and the largest Therapy Area

BioPharmaceuticals
▼ 5%
$11.2bn

36% of revenue. Respiratory & Immunology grew +9%, CVRM (−12%), Infectious Disease (-26%)

Rare Disease
▲ 11%
$4.9bn

16% of revenue


What were the pipeline highlights?

183

projects in our pipeline

116

new molecular entities (NMEs) or major life-cycle management in Phase II or Phase III

21

NMEs in our late-stage pipeline

4

NMEs under review


Matthew Bowden
Company Secretary
AstraZeneca PLC

References

1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.

2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.

3. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.

tags

  • Corporate and financial